Xilio Therapeutics (NASDAQ:XLO – Get Free Report) and Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Profitability
This table compares Xilio Therapeutics and Agios Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xilio Therapeutics | -34.06% | -71.99% | -20.43% |
| Agios Pharmaceuticals | -418.24% | -35.67% | -33.06% |
Analyst Ratings
This is a breakdown of current ratings for Xilio Therapeutics and Agios Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xilio Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Agios Pharmaceuticals | 1 | 4 | 5 | 1 | 2.55 |
Institutional and Insider Ownership
54.3% of Xilio Therapeutics shares are owned by institutional investors. 7.4% of Xilio Therapeutics shares are owned by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Xilio Therapeutics and Agios Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xilio Therapeutics | $43.77 million | 1.35 | -$35.04 million | ($1.64) | -5.49 |
| Agios Pharmaceuticals | $54.03 million | 36.57 | -$412.78 million | ($7.01) | -4.72 |
Xilio Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Xilio Therapeutics has a beta of -0.14, meaning that its share price is 114% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
Summary
Agios Pharmaceuticals beats Xilio Therapeutics on 9 of the 15 factors compared between the two stocks.
About Xilio Therapeutics
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
